SPK-601
Based on 1 Customer Validation
SPK-601 (LMV-601) is an inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC). SPK-601 also can be used as an antimicrobial agent.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.60%
- CAS No.: 1096687-52-3
- Formule: C11H15KOS2
- Masse moléculaire:266.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-70072
D609PC-PLC Inhibitor -
HY-13419
U-73122Phospholipase C Inhibitor -
HY-19619
m-3M3FBSPhospholipase C Activator -
HY-13402
VarespladibsPLA2 Inhibitor -
HY-10521
DarapladibLp-PLA2 Inhibitor -
HY-100736
ML348APT1/LYPLA1 Inhibitor -
HY-N0134
Tanshinone IPhospholipase Inhibitor -
HY-108630
U-73343U-73122 Negative Control -
HY-12807
FIPIPLD Inhibitor -
HY-P0233
MelittinPLA2 Activator -
HY-103334
MAFPcPLA2/iPLA2 Inhibitor -
HY-10801
CAY10650cPLA2α Inhibitor
Voir tous les produits spécifiques à Isoform Phospholipase
More
Activité biologique
Description
IC50 & Target
PC-PLC[1]
In Vitro
SPK-601 (72 hours; HPV-31 cells) displays a dose dependent inhibitory effect on cell growth (IC50 of 16 μg/mL), and inhibits HPV-31 specific RNA expression and DNA replication[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:9E human papilloma virus (HPV)-31 infected cervical epithelial cells
-
Concentration:
-
Incubation Time:72 hours
-
Result:A dose dependent inhibitory effect on cell growth.
Chemical Information
-
CAS No. 1096687-52-3
-
Appearance Solid
-
Masse moléculaire 266.46
-
Formule C11H15KOS2
-
Color Off-white to light yellow
-
SMILES
[H][C@]12[C@@]3([C@H](C[C@]([H])([C@@]1([H])CCC2)C3)OC(S[K])=S)[H]
-
Synonyms
LMV-601
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvant et solubilité
In Vitro:
DMSO : ≥ 1 mg/mL (3.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Pureté et documentation
-
Fiche technique (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7528 mL | 18.7642 mL | 37.5285 mL | 93.8211 mL |
SPK-601 Related Classifications
HY-70083 Related Classifications
Powered by Bioz